E
Erydel
Biotech & Life Sciences · Bresso, Italy · Founded 2007
Red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases MoreLess
EryDel is a biotechnology company focused on developing and commercializing specialized therapies for the treatment of rare diseases. The company utilizes a proprietary platform technology that encapsulates therapeutic enzymes and other molecules within red blood cells. This innovative approach allows for prolonged half-life in circulation, reduced immunogenicity, better tolerability, and predictable vascular distribution. EryDel primarily serves patients suffering from rare diseases, offering them advanced therapeutic options that are not widely available in the market. The company operates in the biopharmaceutical sector, targeting niche markets with high unmet medical needs. EryDel's business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through the sale of these specialized treatments, as well as potential partnerships and licensing agreements with other pharmaceutical companies.
Keywords: biotechnology, rare diseases, red blood cell encapsulation, therapeutic enzymes, prolonged half-life, reduced immunogenicity, better tolerability, vascular distribution, biopharmaceutical, niche markets.
Company overview
Erydel company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2007
- Headquarters
- Bresso, Italy
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 67.3
Valuation & funding
Erydel funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2023 | $485M | $485M | Quince Therapeutics | ↗ |
| SERIES COther financing | Feb 2020 | $23M | $92M | Sofinnova Partners | — |
| SERIES BOther financing | Apr 2018 | $29M | $117M | Innogest Capital · Genextra · Sofinnova Partners | ↗ |
| SERIES BOther financing | Jul 2013 | $17M | $66M | Finlombarda Gestioni SGR · Genextra · Innogest Capital | ↗ |
| SERIES AOther financing | Dec 2008 | $2.8M | $11M | Innogest Capital | — |
| SPINOUTOther financing | Feb 2007 | University of Urbino | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $1.8M | 0% | −$16M | -883.4% |
| 2025 | $1.8M | 0% | −$16M | -883.4% |
| 2024 | $1.8M | +2.1% | −$16M | -883.4% |
| 2023 | $1.8M | +15.9% | −$16M | -901.9% |
| 2022 | $1.5M | — | −$16M | -1045% |
| 2021 | $0 | -100% | −$16M | — |
| 2020 | $106 | — | −$18M | -17121881.1% |
Growth signals
Erydel website traffic
Latest recorded traffic for Erydel is 280 monthly website visits, up 55.6% over the last three months. Erydel's team declined 34.6% over the past year.
Comparisons
Erydel compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Erydel's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Erydel has talent and traffic
team presence
In the news
Latest news about Erydel
Recent press, funding announcements, and product moves mentioning Erydel — open to read from the original sources.
Market sentiment
What the market is saying about Erydel
An AI-synthesized read of the highest-engagement posts about Erydel on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Erydel’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.